



Furthermore, delavirdine (Rescriptor) is a novel HIV-1 reverse transcriptase inhibitor for HIV-positive individuals and zafirlukast (Accolate) is an antiasthma drug.



Bristol-Myers Squibb's thiophene-containing clopidogrel (Plavix) inhibits platelet aggregation induced by adenosine diphosphate (ADP), a platelet activator that is released from red blood cells, activated platelets, and damaged endothelial cells. Clopidogrel, launched in 1993, achieved great commercial success. But its mechanism of action (MOA) was not elucidated until 1999: through the antagonism of the P2Y₁₂ purinergic receptor and prevention of binding of ADP to the P2Y₁₂ receptor by its active metabolite. Therefore, clopidogrel is a *bona fide* pro-drug.



Eli Lilly's raloxifene (Evista) is a selective estrogen receptor modulator (SERM) indicated for osteoporosis and breast cancer. Its core structure is a benzothiophene.